AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Complement component C8 alpha chain including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Complement component C8 alpha chain therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Complement component C8 alpha chain, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Complement component C8 alpha chain. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Complement component C8 alpha chain. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Complement component C8 alpha chain includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Complement component C8 alpha chain
partner:
Reaxense
upacc:
P07357
UPID:
CO8A_HUMAN
Alternative names:
Complement component 8 subunit alpha
Alternative UPACC:
P07357; A2RUI4; A2RUI5; Q13668; Q9H130
Background:
The Complement component C8 alpha chain, also known as Complement component 8 subunit alpha, is a crucial part of the membrane attack complex (MAC). This complex plays a pivotal role in both innate and adaptive immunity by forming pores in the plasma membrane of target cells, leading to cell lysis. The C8A subunit, encoded by the gene with accession number P07357, is essential for inserting into the target membrane, although it does not form pores by itself.
Therapeutic significance:
Complement component 8 deficiency, 1, a rare disease linked to this protein, results in increased susceptibility to severe recurrent infections, especially by Neisseria species. Understanding the role of Complement component C8 alpha chain could open doors to potential therapeutic strategies for enhancing immune response and preventing these infections.
